ZCA
SAGE

Zeke Capital Advisors’s Sage Therapeutics SAGE Stock Holding History

Zeke Capital Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-3,041
Closed -$427K – 567
2019
Q3 		$427K Buy
+3,041
New +$509K 0.04% 396
2018
Q3 		– Sell
-2,272
Closed -$356K – 733
2018
Q2 		$356K Buy
2,272
+249
+12% +$39.1K 0.03% 365
2018
Q1 		$326K Buy
2,023
+74
+4% +$12.6K 0.03% 420
2017
Q4 		$321K Buy
+1,949
New +$189K 0.03% 377

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Zeke Capital Advisors's SAGE Position: Q4 2019 in Review

Zeke Capital Advisors sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 3,041 shares — an estimated $427K sold.

Zeke Capital Advisors first reported a position in SAGE in Q4 2017 and held it in 4 quarters. The position peaked at $427K in Q3 2019. 267 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Zeke Capital Advisors reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Zeke Capital Advisors sold 3,041 Sage Therapeutics shares in Q4 2019, an estimated $427K.
  • Zeke Capital Advisors first reported a position in Sage Therapeutics in Q4 2017 and held it in 4 quarters.
  • Zeke Capital Advisors's Sage Therapeutics position peaked at $427K in Q3 2019.
  • 267 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Zeke Capital Advisors's 13F filing for Q4 2019, filed 17 Jan 2020.